CS
Chris Schott JP Morgan Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Eli Lilly
LLY
$673B
| $750.61 | $1,100 |
47%
upside
| Overweight |
8 Aug ‘25
1 month ago |
|
2
Perrigo
PRGO
$3.07B
| $22.28 | $35 |
57%
upside
| Overweight |
7 Aug ‘25
1 month ago |
|
3
Idexx Laboratories
IDXX
$52.2B
| $655.60 | $675 |
3%
upside
| Overweight |
4 Aug ‘25
1 month ago |
|
4
Regeneron Pharmaceuticals
REGN
$59B
| $556.53 | $800 |
44%
upside
| Overweight |
9 Jun ‘25
3 months ago |
|
5
Teva Pharmaceuticals
TEVA
$22.6B
| $19.68 | $23 |
17%
upside
| Overweight |
12 May ‘25
4 months ago |
|
6
Biogen
BIIB
$21.1B
| $143.60 | $175 |
22%
upside
| Neutral |
5 May ‘25
4 months ago |
|
7
Gilead Sciences
GILD
$144B
| $115.76 | $130 |
12%
upside
| Overweight |
27 Mar ‘25
5 months ago |
|
8
Amneal Pharmaceuticals
AMRX
$3.11B
| $9.89 | $12 |
21%
upside
| Overweight |
24 Feb ‘25
6 months ago |
|
9
AbbVie
ABBV
$372B
| $210.42 | $200 |
5%
downside
| Overweight |
13 Nov ‘24
10 months ago |
|
10
Zoetis
ZTS
$67.3B
| $149.79 | $230 |
54%
upside
| Overweight |
11 Oct ‘24
11 months ago |
|
11
Organon & Co
OGN
$2.7B
| $10.37 | $20 |
93%
upside
| Underweight |
6 Sep ‘24
1 year ago |
|
12
Royalty Pharma
RPRX
$15.5B
| $36.50 | $42 |
15%
upside
| Overweight |
20 Feb ‘24
1 year ago |
|
13
Amgen
AMGN
$151B
| $279.97 | $270 |
4%
downside
| Neutral |
20 Oct ‘23
1 year ago |
|
14
Pfizer
PFE
$140B
| $24.71 | $34 |
38%
upside
| Neutral |
16 Oct ‘23
1 year ago |
|
15
Merck
MRK
$211B
| $84.61 | $125 |
48%
upside
| Overweight |
23 Feb ‘23
2 years ago |
|
16
Viatris
VTRS
$12.2B
| $10.45 | $14 |
34%
upside
| Neutral |
15 Nov ‘22
2 years ago |
|
17
Coherus Oncology, Inc. Common Stock
CHRS
$159M
| $1.35 | $11 |
715%
upside
| Neutral |
14 Nov ‘22
2 years ago |
|
18
Elanco Animal Health
ELAN
$9.32B
| $18.76 | $20 |
7%
upside
| Neutral |
17 Oct ‘22
2 years ago |
|
19
Bristol-Myers Squibb
BMY
$96.1B
| $47.23 | $78 |
65%
upside
| Overweight |
16 Oct ‘20
4 years ago |
|
20
KALA BIO
KALA
$102M
| $14 | $950 |
6,686%
upside
| Overweight |
27 May ‘20
5 years ago |
|